Theravance Biopharma Inc. (NASDAQ:TBPH) and Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) compete against each other in the Biotechnology sector. We will contrast them and contrast their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma Inc.	60.37M	21.83	215.52M	-4.72	0.00
Catabasis Pharmaceuticals Inc.	N/A	0.00	25.87M	-80.26	0.00

In table 1 we can see Theravance Biopharma Inc. and Catabasis Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 has Theravance Biopharma Inc. and Catabasis Pharmaceuticals Inc.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma Inc.	-357.00%	-520.6%	-60.6%
Catabasis Pharmaceuticals Inc.	0.00%	-91.2%	-76.8%

Risk & Volatility

Theravance Biopharma Inc.’s 1.77 beta indicates that its volatility is 77.00% more volatile than that of Standard and Poor’s 500. Competitively, Catabasis Pharmaceuticals Inc.’s beta is 1.62 which is 62.00% more volatile than Standard and Poor’s 500.

Liquidity

The Current Ratio and a Quick Ratio of Theravance Biopharma Inc. are 3.3 and 3.1. Competitively, Catabasis Pharmaceuticals Inc. has 10.8 and 10.8 for Current and Quick Ratio. Catabasis Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Theravance Biopharma Inc.

Analyst Recommendations

The table delivered features the ratings and recommendations for Theravance Biopharma Inc. and Catabasis Pharmaceuticals Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Theravance Biopharma Inc.	0	0	2	3.00
Catabasis Pharmaceuticals Inc.	0	0	1	3.00

Theravance Biopharma Inc. has an average target price of $47.5, and a 102.21% upside potential. Competitively the consensus target price of Catabasis Pharmaceuticals Inc. is $46, which is potential 410.54% upside. The data provided earlier shows that Catabasis Pharmaceuticals Inc. appears more favorable than Theravance Biopharma Inc., based on analyst belief.

Institutional and Insider Ownership

Institutional investors owned 87.4% of Theravance Biopharma Inc. shares and 24.1% of Catabasis Pharmaceuticals Inc. shares. Theravance Biopharma Inc.’s share owned by insiders are 5.7%. Insiders Comparatively, owned 1.93% of Catabasis Pharmaceuticals Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Theravance Biopharma Inc.	-0.37%	-6.1%	-8.46%	-14.12%	-7.96%	-4.42%
Catabasis Pharmaceuticals Inc.	0.2%	-21.98%	-20.76%	-35.96%	-75.03%	13.73%

For the past year Theravance Biopharma Inc. had bearish trend while Catabasis Pharmaceuticals Inc. had bullish trend.

Summary

Catabasis Pharmaceuticals Inc. beats on 6 of the 10 factors Theravance Biopharma Inc.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. Its product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases. The companyÂ’s product candidates also comprise Axelopran, an oral peripherally active mu opioid receptor antagonist that is in Phase II clinical trials for opioid induced constipation; Velusetrag (TD-5108), an oral and investigational medicine, which is in Phase II studies for gastrointestinal motility disorders; TD-8954, a selective 5-HT4 receptor agonist for gastrointestinal motility disorders; and TD-1473, a pan-Janus kinase inhibitor, which has completed phase I clinical studies for ulcerative colitis. In addition, it develops TD-0714, a Neprilysin inhibitor that has completed phase I clinical studies for heart failure and chronic kidney diseases; and TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor, which is in Phase II clinical studies for neurogenic orthostatic hypotension. Further, the company focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol for the treatment of COPD and asthma; the Inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company offers Edasalonexent, an investigational oral small molecule, which is in Phase I/II clinical trial for the treatment of duchenne muscular dystrophy (DMD). It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis. The company has preclinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD. Catabasis Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.